Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Goals
Fat LossMuscle BuildingInjury HealingAnti-AgingCognitive EnhancementSleep OptimizationImmune SupportGut HealingSkin RejuvenationSexual Health
Peptides
Adipotide
Weight Management
AOD-9604
Weight Management
BPC-157
Healing & Recovery
Cagrilintide
Weight Management
CJC-1295
Growth Hormone
DSIP
Sleep & Recovery
Epithalon
Anti-Aging
GHK-Cu
Anti-Aging
GHRP-2
Growth Hormone
HCG
Hormone Support
Hexarelin
Growth Hormone
HGH
Growth Hormone
IGF-1 LR3
Growth Hormone
Kisspeptin
Hormone Support
Melanotan-2
Cosmetic
MOTS-C
Metabolic
NAD+
Anti-Aging
Oxytocin Acetate
Hormone Support
PEG-MGF
Recovery
PNC-27
Cancer Research
PT-141
Sexual Health
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Snap-8
Cosmetic
SS-31
Mitochondrial
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Thymosin Alpha-1
Immune
Tirzepatide
Weight Management
Total Peptides: 32
Back to Home

Peptide Comparison

Cathelicidin (hCAP-18 / Synthetic Derivatives)vsThymalin

Human cationic antimicrobial protein-18 (hCAP-18) precursor and its synthetic derivative SAAP-148 — a next-generation 24-amino-acid cathelicidin-based peptide with broad-spectrum bactericidal activity against multidrug-resistant ESKAPE pathogens including MRSA biofilms, superior potency to its parent fragment LL-37, and retained efficacy under physiological salt and plasma conditions

Russian thymic peptide complex that rejuvenates immune function and supports healthy aging

ImmuneImmune

At a Glance

Quick
comparison

Dose Range

Cathelicidin (hCAP-18 / Synthetic Derivatives)

0.5–5 mg

Thymalin

5–10 mg

Frequency

Cathelicidin (hCAP-18 / Synthetic Derivatives)

Once daily

Thymalin

Once daily

Administration

Cathelicidin (hCAP-18 / Synthetic Derivatives)

Topical application (primary research route)

Thymalin

Intramuscular injection

Cycle Length

Cathelicidin (hCAP-18 / Synthetic Derivatives)

4-6 weeks

Thymalin

4-6 weeks

Onset Speed

Cathelicidin (hCAP-18 / Synthetic Derivatives)

Rapid (hours to days)

Thymalin

Moderate (1-2 weeks)

Evidence Level

Cathelicidin (hCAP-18 / Synthetic Derivatives)

Moderate human trials (Phase 1-2)

Thymalin

Limited human trials

Efficacy

Benefit
ratings

Cathelicidin (hCAP-18 / Synthetic Derivatives)
Thymalin

Healing

Cathelicidin (hCAP-18 / Synthetic Derivatives)92%
Thymalin0%

Immune

Cathelicidin (hCAP-18 / Synthetic Derivatives)85%
Thymalin0%

Immune Restoration

Cathelicidin (hCAP-18 / Synthetic Derivatives)0%
Thymalin88%

Longevity Support

Cathelicidin (hCAP-18 / Synthetic Derivatives)0%
Thymalin82%

Disease Prevention

Cathelicidin (hCAP-18 / Synthetic Derivatives)0%
Thymalin78%

Technical Data

Compound
specifications

Cathelicidin (hCAP-18 / Synthetic Derivatives)

Molecular Formula

hCAP-18: ~18 kDa precursor protein (170 AA); SAAP-148: C155H253N49O31 (approximate), MW 3,267.1 Da

Molecular Weight

hCAP-18 precursor: ~18,000 Da; SAAP-148: 3,267.1 Da; OP-145: ~2,900 Da

Half-Life

Plasma half-life: minutes (proteolytic degradation); local tissue persistence: hours at therapeutic concentrations in wound environment; enhanced stability compared to LL-37 due to N-terminal acetylation and C-terminal amidation

Bioavailability

Topical bioavailability optimized in hypromellose ointment formulations; SAAP-148 retains activity in human plasma unlike LL-37; systemic bioavailability limited by proteolytic degradation

CAS Number

Not assigned (SAAP-148 and OP-145 are novel synthetic derivatives)

Thymalin

Molecular Formula

Complex mixture; active dipeptide EW: C16H19N3O5

Molecular Weight

Polypeptide complex; components 250-1000 Da; active dipeptide EW ~321 Da

Half-Life

Not precisely characterized for complex; immune effects persist weeks post-administration

Bioavailability

High via intramuscular or subcutaneous injection

CAS Number

63958-90-7

Protocols

Dosing
tiers

Cathelicidin (hCAP-18 / Synthetic Derivatives)

starting

0.5-1 mg topically or 1.6 µM in research protocols

Once to twice daily

3-5 days initial assessment

Begin with low-concentration topical application in wound care research protocols. SAAP-148 has been studied in ointment formulations (hypromellose-based) for localized wound infections. Apply to clean wound bed and cover with appropriate dressing. Monitor for local irritation or inflammatory response. In vitro studies use 1.6-6.4 µM for planktonic bacteria. This is an investigational compound — use under research supervision only.

standard

2-3 mg topically or 6.4-12.8 µM in research protocols

Once to twice daily

7-10 days

Standard preclinical research concentration range effective against planktonic ESKAPE pathogens and early biofilms. SAAP-148 at 6.4 µM eliminates most planktonic MDR bacteria within 30 minutes. Topical ointment formulations have been used in ex vivo human skin wound infection models. OP-145 was evaluated at 0.5-2 mg/mL in ear drops for chronic otitis media in clinical trials. Combine with appropriate wound care protocols.

advanced

5 mg topically or 25.6 µM in research protocols

Once to twice daily

10-14 days

Higher concentrations used for established biofilm eradication and recalcitrant wound infection models. At 25.6 µM, SAAP-148 eradicates mature MRSA and A. baumannii biofilms. Be aware of dose-dependent hemolytic activity at concentrations >50 µM — stay within the therapeutic window. Extended treatment durations for chronic wound models. Medical supervision required.

Thymalin

starting

5 mg daily

Once daily

5 days

Initial dose to assess tolerance and immune response; best for first-time users

standard

10 mg daily

Once daily

10 days

Standard clinical protocol used in most Russian research studies; most effective dose

advanced

10 mg Thymalin + 5 mg Epitalon daily

Once daily

20 days, repeated every 6 months

Combined peptide protocol for enhanced longevity and geroprotective effects

Applications

Best
suited for

Cathelicidin (hCAP-18 / Synthetic Derivatives)

Research into next-generation antimicrobials against multidrug-resistant infections

Cathelicidin (hCAP-18 / Synthetic Derivatives) is particularly well-suited for individuals focused on research into next-generation antimicrobials against multidrug-resistant infections. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Topical antimicrobial development for wound infections with biofilm involvement

Cathelicidin (hCAP-18 / Synthetic Derivatives) is particularly well-suited for individuals focused on topical antimicrobial development for wound infections with biofilm involvement. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Understanding vitamin D-cathelicidin innate immune axis for immune optimization

Cathelicidin (hCAP-18 / Synthetic Derivatives) is particularly well-suited for individuals focused on understanding vitamin d-cathelicidin innate immune axis for immune optimization. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Development of anti-biofilm therapeutics for chronic device-related and wound infections

Cathelicidin (hCAP-18 / Synthetic Derivatives) is particularly well-suited for individuals focused on development of anti-biofilm therapeutics for chronic device-related and wound infections. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Thymalin

Aging Adults Seeking Immune Support

Thymalin is especially valuable for people over 55 whose thymus gland has naturally shrunk with age. By stimulating thymic function, it helps restore the immune training center that your body relies on to fight infections and stay healthy.

Longevity and Anti-Aging Protocols

Clinical studies tracking patients for 6-8 years showed Thymalin reduced mortality by 2.0-2.1-fold. Combined with Epitalon, the mortality reduction reached an impressive 4.1-fold, making this combination one of the most studied longevity peptide protocols.

Seasonal Illness Prevention

Research shows Thymalin cuts respiratory infection rates by 2.0-2.4-fold. A short 10-day course before cold and flu season can significantly boost your immune defenses for months afterward.

Safety Profile

Side
effects

Cathelicidin (hCAP-18 / Synthetic Derivatives)

Common

  • Local application site irritation
  • Local inflammatory response
  • Mild wound exudate increase

Uncommon

  • Localized urticaria
  • Transient pain at injection site

Serious

  • Hemolytic activity at supratherapeutic doses

Thymalin

Common

  • No side effects in most patients
  • Mild injection site reaction

Uncommon

  • Transient low-grade fever
  • Mild flu-like symptoms
  • Temporary headache

Serious

  • Severe allergic reaction

Research Status

Safety
& evidence

Cathelicidin (hCAP-18 / Synthetic Derivatives)

Evidence Level

Moderate human trials (Phase 1-2)

FDA Status

Research compound

Safety Overview

Cathelicidin peptides (natural and synthetic) are not FDA-approved and have no completed human clinical trials. Animal studies demonstrate broad-spectrum antimicrobial activity without systemic toxicity at therapeutic concentrations. However, concern exists regarding immunological tolerance—cathelicidin derivatives can trigger innate immune activation and inflammatory responses at high concentrations. The peptide's mechanism on immune cells is incompletely understood in humans, and effects on chronic immune signaling, tolerance development, or off-target immune activation remain uncharacterized. Bacterial resistance development to cathelicidin-based therapeutics is theoretically possible but not yet documented clinically.

Contraindications

  • xKnown hypersensitivity to cathelicidin-derived peptides or formulation components
  • xPregnancy and breastfeeding — insufficient reproductive safety data for synthetic derivatives
  • xActive autoimmune conditions involving cathelicidin dysregulation (e.g., rosacea, psoriasis) — exogenous cathelicidin peptides may exacerbate inflammation
  • xSevere systemic immunodeficiency without medical supervision — immune modulation effects may be unpredictable

Thymalin

Evidence Level

Limited human trials

FDA Status

Research compound

Safety Overview

Thymalin has an excellent safety profile based on over 40 years of clinical use in Russia. Most patients experience zero side effects, and the peptide complex has been described as 'practically non-toxic' in research literature. It has been used safely in thousands of patients, including elderly populations over extended periods.

Contraindications

  • xActive thymic tumors or malignancies
  • xKnown hypersensitivity to animal-derived peptide products
  • xPregnancy and breastfeeding (insufficient safety data)
  • xSevere uncontrolled autoimmune disease without medical supervision

Decision Guide

Which is
right for you?

Choose Cathelicidin (hCAP-18 / Synthetic Derivatives) if...

  • Research into next-generation antimicrobials against multidrug-resistant infections
  • Topical antimicrobial development for wound infections with biofilm involvement
  • Understanding vitamin D-cathelicidin innate immune axis for immune optimization
  • Development of anti-biofilm therapeutics for chronic device-related and wound infections

Choose Thymalin if...

  • Immune system restoration in aging adults
  • Longevity and healthy aging support
  • Reducing infection frequency and severity
  • Multi-system health optimization